CA Patent

CA2897719A1 — Use of dpp iv inhibitors

Assigned to Boehringer Ingelheim International GmbH · Expires 2007-11-15 · 19y expired

What this patent protects

Disclosed is the use of DPP-IV inhibitors for treating physiological functional disorders and reducing the risk of at-risk patient groups developing such functional disorders.

USPTO Abstract

Disclosed is the use of DPP-IV inhibitors for treating physiological functional disorders and reducing the risk of at-risk patient groups developing such functional disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2897719A1
Jurisdiction
CA
Classification
—
Expires
2007-11-15
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.